Clinical trial
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With…
NCT00328497 · CASI Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00328497 |
|---|---|
| Title | A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors |
| Official title | A Phase 1-2 Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With rhuMAb VEGF (Bevacizumab) in Patients With Locally Advanced or Metastatic Carcinoid Tumors |
| Lead sponsor | CASI Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoid Tumor |
| Intervention type | Drug |
| Interventions | Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) |
| Enrollment | 31 |
| Start date | May 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | May 22, 2006 |
| Last update posted | Mar 10, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: